Listenly

What is the market size potential for Grail's multi-cancer early detection screening test?

Answered at 21:14 in Ensemble Capital Second Quarter 2024 Portfolio Update · Intrinsic Investing

— questions searchable right now

What is the market size potential for Grail's multi-cancer early detection screening test?

Grail's multi-cancer early detection screening (MCED) test could detect 50 different types of cancer from a single non-invasive blood drop across a market that could be as large as hundreds of millions of people globally. Currently, only standardized tests exist for five types of cancer—breast, prostate, colon, cervical, and lung—while about 8% of cancer deaths occur from cancers without recommended screening.

Unknown on Intrinsic InvestingAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Grail's multi-cancer early detection screening (MCED) test could detect 50 different types of cancer from a single non-invasive blood drop across a market that could be as large as hundreds of millions of people globally.

Guest · Ensemble Capital Second Quarter 2024 Portfolio Update · Intrinsic Investing · answer at 21:14

Key takeaways

  • Grail's multi-cancer early detection screening (MCED) test could detect 50 different types of cancer from a single non-invasive blood drop across a market that could be as large as hundreds of millions of people globally.

Quote to remember

“Either the largest companies in the world will gobble up a larger share of profits than has ever occurred in the U.S., or the average stock will perform much better than the S&P 500 in the years ahead, as the excessive outperformance of these mega cap stocks reverts, as it has in every past instance.”

The full answer · about 3 min

Grail's multi-cancer early detection screening (MCED) test could detect 50 different types of cancer from a single non-invasive blood drop across a market that could be as large as hundreds of millions of people globally. Currently, only standardized tests exist for five types of cancer—breast, prostate, colon, cervical, and lung—while about 8% of cancer deaths occur from cancers without recommended screening.

Key facts

  • S&P 500 returned 15.3% in first half of 2024; Ensemble Capital strategy returned 8%
  • Average stock in S&P 500 up only 5% in first half of 2024
  • Magnificent Seven stocks up 94.9% over five-quarter period versus 16.2% for average stock
  • NVIDIA up 345% over past five quarters; up 2,926% over past five years versus S&P 500 up 101%
  • Five largest companies in S&P 500 make up 25% of entire index—most intense concentration in at least half a century

People, companies and topics mentioned

Ensemble CapitalIntrinsic InvestingS&P 500Magnificent SevenNVIDIATeslaAmazonApple

More answers from this episode

 ·  All answers from Intrinsic Investing →
—
—
0:00
0:00